Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479945 | 0.85 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2KDM4E | |
| SCHEMBL5485434 | 0.79 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3883718 | 0.78 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL17836550 | 0.74 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL5483313 | 0.74 | NPC1 (0.38) | MAP2K1MAP2K2PRKCZIARS2ALDH1A1 | |
| SCHEMBL3888625 | 0.74 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5480986 | 0.74 | MAP2K1 (0.43) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5485309 | 0.74 | MAP2K1 (0.45) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3956955 | 0.74 | MAP2K1 (0.51) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5479957 | 0.74 | NPC1 (0.41) | MAP2K1MAP2K2PRKCZIARS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | claimed |
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| CN-101426766-A | Novel heteroaryl substituted arylaminopyridine derivatives as MEK inhibitors | SERONO LAB (CH) | 2009-05-06 | — | — | CN | disclosed |
| EP-2013180-A1 | NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS | Laboratoires Serono SA (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| WO-2007123936-A1 | NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS | LABORATOIRES SERONO SA (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | MAP2K1 40/4885MAP2K2 27/4885PRKCZ 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.